Javascript was detected to be disabled. Javascript is required for some functions on this website.

Selected Scientific Presentations

2014-2010

2014

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
17th Annual European Congress, Amsterdam / The Netherlands, November 08-12, 2014:

Michael Schlander, Silvio Garattini, Søren Holm, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol Sola Morales, Keith Tolley, Mondher Toumi:

The Evaluation of Economic Methods to Assess the Social Value of Medical Interventions for Ultra-Rare Disorders (URDs).

(Plenary Presentation)
Abstract published in Value in Health 17 (7), 2014: A324.

Michael Schlander, Afschin Gandjour:

Budget Impact Analysis of Drugs for Ultra-Rare Non-Oncological Diseases in Europe.

(Poster presentation)
Abstract published in Value in Health 17 (7), 2014: A525.

Swiss Medical Board (SMB)
October / November 2014:

Pro bono contributions to the further conceptual development of the SwissHTA convergence initiative and the Swiss Medical Board (SMB)

Michael Schlander:

HTA & Stakeholder Involvement – International References.

(Invited Presentation, Bern / Switzerland, November 19, 2014)

Michael Schlander:

HTA & Topic Selection / Scoping – International References.

(Invited Presentation, Bern / Switzerland, October 07, 2014)

See also the earlier comment on SMB in Neue Zürcher Zeitung (NZZ) of November 14, 2013 (p. 23):

“Why the SMB is not good enough” – German: “Warum das Swiss Medical Board nicht genügt.”

Rare Diseases and Orphan Drug Symposium and Orphan Drug Regulation Workshop
[Ilac Bilincini Gelistirme ve Akilci Ilac Dernegi]
Antalya / Turkey, September 13 (/14), 2014:

Michael Schlander:

Interventions for Rare / Ultra-Rare Disorders and the Logic of Cost Effectiveness.

(Invited Presentation)

11th Annual HTAi Meeting 2014
Grand Hyatt Washington, Washington, DC / USA, June 14-18, 2014:

Michael Schlander, Silvio Garattini, Sören Holm, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol Sola Morales, Keith Tolley, Mondher Toumi:

Interventions for Ultra-Rare Disorders (URDs):  How to Assess “Value for Money”?

(Oral Presentation, session on “Valuing Health – Past, Present, and Future”, Washington, DC, June 16, 2014)

M. Schlander, C. Affolter, T.B. Cueni, H. Sandmeier for the SwissHTA Group:

Health Technology Assessment (HTA) in Switzerland: The “SwissHTA” Multi-Stakeholder Consensus.

(Oral presentation, session on “How to Improve Resource Allocation”, Washington, DC, June 16, 2014)

2013

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
16th Annual European Congress , Dublin / Ireland, November 02-06, 2013:

Michael Schlander, Munir A. Khan, Angelo Iezzi, Aimee Maxwell, Oliver Schwarz, Jeff Richardson:

The Measurement of Health-Related Quality of Life: First German Findings from the Multi-Instrument Comparison (MIC) Study.

Value in Health 16 [7] (2013) A330.

European Society for Child and Adolescent Psychiatry (ESCAP)
15th International ESCAP Congress
Dublin, Ireland, July 06-10, 2013:

Michael Schlander et al.:

Attention-Deficit/Hyperactivity Disorder (ADHD):
A Longitudinal Analysis (2003-2009) of Prevalence, Health Care, and Direct Cost based upon Administrative Data from Nordbaden / Germany.

(Scientific Symposium)

4th World Congress on Attention-Deficit/Hyperactivity Disorder (ADHD) - From Childhood to Adult Disease
Milan, Italy, June 07, 2013:

Michael Schlander:

The Costs and Benefits of Attention-Deficit/Hyperactivity Disorder - An Economic View.

(Invited Plenary Presentation)
Abstract published in Attention-Deficit/Hyperactivity Disorders [ADHD] Vol. 5 (2), 2013: 113.

European Pricing Platform (EPP)
3rd EPP Life Sciences Forum, Montreux, Switzerland, June 05, 2013:

Michael Schlander:

Europe - Problem Child or Rising Star? Outlook and Opportunities for Growth.

(Invited Keynote Presentation)

2012

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
15th Annual European Congress, Berlin, Germany, November 03-07, 2012:

Scientific Program Chair on Congress Highlights

Michael Schlander et al.:

The Swiss Health Technology Assessment (HTA) Consensus: Guiding Principles.

(Abstract) Value in Health 15 (7), 2012: A319.

Michael Schlander et al.:

Involvement of CNS Specialists in Health Care Provision for Patients with Attention-Deficit/Hyperactivity Disorder (ADHD).

(Abstract) Value in Health 15 (7), 2012: A344.

Michael Schlander and Oliver Schwarz:

Health Care Utilization Research in Germany: Characterization of the Nordbaden Database.

(Abstract) Value in Health 15 (7), 2012: A303.

9th European Conference on Health Economics (ECHE)
Zurich, Switzerland, July 18-21, 2012:

Michael Schlander et al.:

Will Progress in Applied Health Economics Depend on a New Evaluation Paradigm?

12th International Symposium on MPS and Related Diseases
Amsterdam (Noordwijkerhout), The Netherlands, June 30, 2012:

Michael Schlander:

Cost Effectiveness and Orphan Drugs.

(Invited Plenary Presentation)

Interview on Noordwijkerhout Symposium

2011

International Society for Pharmacoeconomics and Outcomes Research (ISPOR),
14th Annual European Congress, Madrid, Spain, November 05-08, 2011:

Michael Schlander, Oliver Schwarz, et al.:

Increasing Use of Medication for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Germany Between 2003 and 2009.

(Abstract) Value in Health 14 (7) 2011: A300.

Michael Schlander, Alexandra Philipsen, et al.:

The Cost Effectiveness of Clinically Proven Treatment Strategies for Attention-Deficit/Hyperactivity Disorder in Adult Patients.

(Abstract) Value in Health14 (7) 2011: A403.

UK Adult ADHD Network (UKAAN), First European Adult ADHD Conference
Savoy Place, London, England, September 23, 2011:

Michael Schlander:

ADHD across the lifespan – what are the costs to society?

2010

Verein für Socialpolitik, Ausschuss für Gesundheitsökonomie
Augsburg, Germany, October 16, 2010:

Michael Schlander, Munir Khan, John McKie, and Jeff Richardson:

Health-Realted Quality of Life (HRQoL) Instruments: Some Prerequisites for Their Appropriate Use in Economic Evaluation.